TCS 1102

Key Product Details

Product Description

TCS 1102 is a potent, dual orexin receptor antagonist (K_i values are 0.2 and 3 nM for OX₂ and OX₁ receptors respectively). Inhibits ADL-orexin B-mediated locomotion following i.p. administration in vivo and blocks orexin-A (Cat.No.1455) mediated increases in feeding behaviour. Brain penetrant.

Licensing Information

Manufactured and sold under license from Merck & Co., Inc. for use solely for preclinical research purposes (ie: not for administration to or other use in humans)

Product Specifications for TCS 1102

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for TCS 1102

The following data is based on the product molecular weight 470.59.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.12 mL	10.62 mL	21.25 mL
5 mM	0.42 mL	2.12 mL	4.25 mL
10 mM	0.21 mL	1.06 mL	2.12 mL
50 mM	0.04 mL	0.21 mL	0.42 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 32 publications citing the usage of this product.

• Bergman Proline bis-amides as potent dual orexin receptor antagonists. Bioorg.Med.Chem.Letts
• Khoo The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking. PLoS One 2017 PMID: 28296947
• Winrow Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 2010 PMID: 19596018

Product Documents for TCS 1102